NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02588170,Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors,https://clinicaltrials.gov/study/NCT02588170,,COMPLETED,"A randomized, double-blind, placebo controlled, multi-center Phase III study to assess the efficacy of Surufatinib 300 mg once a day in treating advanced extrapancreatic neuroendocrine tumors.",NO,Neuroendocrine Tumors,DRUG: Surufatinib|OTHER: Placebo,"Progression Free Survival (PFS), the duration between the randomization date and the first disease progression (PD) or death (whichever comes first)., 9 months after the last patient enrolled","The objective response rate of the tumor (ORR), the incidence of confirmed complete response or partial response, 9 months after the last patient enrolled|The disease control rate (DCR), the incidence of complete response, partial response and stable disease, 9 months after the last patient enrolled|Duration of Response (DoR), the duration between the date the criteria for complete response or partial response was first measured (first record shall prevail) and the date of disease recurrence or progression as objectively recorded, 9 months after the last patient enrolled|Time to Response (TTR), the period from the date of randomization to the date when the criteria for complete response or partial response was first measured (first record shall prevail)., 9 months after the last patient enrolled|Overall survival, the time from the date of randomization to the date of death (all causes), 9 months after the last patient enrolled|adverse events evaluated by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03, The safety and tolerability of Surufatinib will be evaluated based on adverse events data. Other safety parameters include physical examination, vital signs, laboratory test results (i.e., hematology, chemistry panel, and urinalysis), 12-lead electrocardiogram, and ultrasonic cardiogram., From first dose to within 30 days after the last dose",,Hutchison Medipharma Limited,,ALL,"ADULT, OLDER_ADULT",PHASE3,219,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2015-012-00CH4,2015-12-07,2019-03-31,2022-07-07,2015-10-27,,2023-03-30,"Peking Union Medical College Hospital, Beijing, Beijing, 100032, China|the 307 Hospital of People's Liberation Army, Beijing, Beijing, 100071, China|Beijing Cancer Hospital, Beijing, Beijing, 100142, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, China|West China Hospital, Sichuan University, Chengdu, Sichuan, 610047, China",
